Cargando…

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)

AIM: Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC is used in US clinical practice. MATERIALS & METHODS: A chart review was conducted at seven centers, with 78 patients scree...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perez, Matthew C, Zager, Jonathan S, Amatruda, Thomas, Conry, Robert, Ariyan, Charlotte, Desai, Anupam, Kirkwood, John M, Treichel, Sheryl, Cohan, David, Raskin, Leon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2019
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688558/ https://www.ncbi.nlm.nih.gov/pubmed/31406563 http://dx.doi.org/10.2217/mmt-2019-0012

Ejemplares similares

Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)
por: Sun, James, et al.
Publicado: (2020)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
por: Andtbacka, Robert H.I., et al.
Publicado: (2019)

Talimogene laherparepvec: First in class oncolytic virotherapy
por: Conry, Robert M., et al.
Publicado: (2018)

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
por: Blackmon, Jonathan T., et al.
Publicado: (2017)

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
por: McClure, Erin M., et al.
Publicado: (2022)

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
por: Andtbacka, Robert H. I., et al.
Publicado: (2016)

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
por: Dummer, Reinhard, et al.
Publicado: (2017)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases
por: Blackmon, Jonathan T., et al.
Publicado: (2017)

Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
por: Orloff, Marlana
Publicado: (2016)

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection
por: Shmuylovich, Leonid, et al.
Publicado: (2022)

Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
por: Park, Song Y, et al.
Publicado: (2022)

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma
por: Beekman, Kate E., et al.
Publicado: (2023)

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
por: Chesney, Jason A., et al.
Publicado: (2023)

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
por: Swami, Umang, et al.
Publicado: (2019)

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)
por: Mulder, Evalyn E. A. P., et al.
Publicado: (2021)

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
por: Miller, David M., et al.
Publicado: (2018)

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors
por: Chesney, Jason, et al.
Publicado: (2018)

Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients
por: Westbrook, Brian C., et al.
Publicado: (2019)

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
por: Kaufman, Howard L., et al.
Publicado: (2016)

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy
por: Rizzo, Jason M., et al.
Publicado: (2018)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

A practical guide to the handling and administration of talimogene laherparepvec in Europe
por: Harrington, Kevin J, et al.
Publicado: (2017)

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
por: Kaufman, Howard L., et al.
Publicado: (2022)

Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
por: Quinn, Casey, et al.
Publicado: (2016)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
por: Ressler, Julia Maria, et al.
Publicado: (2021)

A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2022)

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy
por: Zhang, Tiantian, et al.
Publicado: (2023)

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Publicado: (2021)

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec
por: Lebhar, Jamie, et al.
Publicado: (2023)

Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma
por: Mulder, Evalyn E.A.P., et al.
Publicado: (2022)

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
por: Andtbacka, Robert H. I., et al.
Publicado: (2019)

Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
por: Fröhlich, Anne, et al.
Publicado: (2020)

Talimogene laherparepvec (T‐VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report
por: Ressler, J., et al.
Publicado: (2019)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
por: Rehman, Hasan, et al.
Publicado: (2016)

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
por: Sun, Lillian, et al.
Publicado: (2018)

Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
por: Kleemann, Johannes, et al.
Publicado: (2021)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
por: Tijtgat, Jens, et al.
Publicado: (2021)

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
por: Kai, Megumi, et al.
Publicado: (2021)

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
por: Singh, Neha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fj2l1bjg5vq1hskacc9kodbdkp